{
  "ticker": "OIL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960775",
  "id": "02960775",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250623",
  "time": "0841",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06kzw4z8w4w2yy.pdf",
  "summary": "**Material Information Summary**  \n\n- **Exclusive Collaboration Agreement** signed with Long Grove Pharmaceuticals (US) for **AK-FLOUR\u00ae** (fluorescein sodium contrast agent), critical for Optiscan\u2019s **InVue\u00ae surgical imaging device**.  \n- **Key objectives**:  \n  - Develop new clinical applications for AK-FLOUR\u00ae in combination with Optiscan\u2019s technology.  \n  - Support **US FDA regulatory submissions** for InVue\u00ae (initial focus: breast surgery, expanding to GI/robotic/laparoscopic applications).  \n  - Potential acceleration of Optiscan\u2019s **US market entry** via Long Grove\u2019s existing drug data (CMC/pharmacokinetic).  \n- **Term**: 5 years (early termination possible by mutual agreement).  \n- **Strategic impact**: Strengthens Optiscan\u2019s **regulatory pathway** and potential commercial reach in the US surgical imaging market.  \n\n*Rationale*: Focused on partnership terms, regulatory/commercial implications, and tangible progress toward FDA approvals. Omitted non-material details (e.g., executive quotes, background on companies).",
  "usage": {
    "prompt_tokens": 2631,
    "completion_tokens": 233,
    "total_tokens": 2864,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-22T23:01:17.380760"
}